Nasus Pharma Ltd. (NSRX)
Automate Your Wheel Strategy on NSRX
With Tiblio's Option Bot, you can configure your own wheel strategy including NSRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NSRX
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 64125901.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -41.8576
- Debt/Assets 0.0
- DivYield 0
- ROE 0.0
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Nasus Pharma CEO Issues 2025 Letter to Shareholders
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman.
Read More
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen
Read More
About Nasus Pharma Ltd. (NSRX)
- IPO Date 2025-08-13
- Website http://www.nasuspharma.com
- Industry Biotechnology
- CEO Dan Teleman
- Employees 2